Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 19/20 | 0.57 |
| ▸ | HTR2C | P28335 | 13/20 | 0.57 |
| ▸ | HTR1A | P08908 | 5/20 | 0.50 |
| ▸ | DRD2 | P14416 | 5/20 | 0.50 |
| ▸ | HTR7 | P34969 | 5/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14045199 | 0.93 | HTR2A (0.55) | HTR2AHTR2CHTR1ADRD2HTR7 | |
| SCHEMBL14045239 | 0.88 | HTR2A (0.56) | HTR2AHTR2CHTR1ADRD2HTR7 | |
| SCHEMBL14045243 | 0.84 | HTR2A (0.54) | HTR2AHTR2CHTR1ADRD2HTR7 | |
| SCHEMBL14045250 | 0.82 | HTR2A (0.58) | HTR2AHTR2CHTR1ADRD2HTR7 | |
| SCHEMBL14625270 | 0.81 | HTR2A (0.76) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL14045062 | 0.80 | HTR2A (0.52) | HTR2AHTR2CHTR1ADRD2HTR7 | |
| SCHEMBL14625133 | 0.79 | HTR2A (0.57) | HTR2AHTR2CHTR1ADRD2HTR7 | |
| SCHEMBL14625146 | 0.79 | DCUN1D1 (0.34) | HTR2AHTR2CHTR1ADRD2HTR7 | |
| SCHEMBL14045248 | 0.78 | HTR2A (0.62) | HTR2AHTR2CHTR1ADRD2HTR7 | |
| SCHEMBL14624530 | 0.77 | HTR2A (0.45) | HTR2AHTR2CL3MBTL1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269170-A1 | Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | US | disclosed |
| WO-2007006926-A2 | NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269170-A1 | Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors | NFKBIA, IKBKB, IKBKE | HTR2A 3453/4885HTR2C 3934/4885HTR1A 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.